Do You See Adult Patients Like This in Your Practice?

Adequately treated with INVEGA SUSTENNA® for at least 4 months, with the last 2 doses being the same:

  • Achieved consistent schizophrenia symptom control
  • Demonstrated established tolerability
  • Consistently receiving monthly injections of INVEGA SUSTENNA®
  • Progressed to stage in treatment journey where he/she is ready to pursue long-term treatment goals with less frequent dosing
Are you offering your adult patients with schizophrenia the option of progressing to the longest dosing interval available?
patient-type

New Clinical Guidance Supports Earlier Use of LAIs in Adults With Schizophrenia3

national-council

The National Council for Behavioral Health and American Association of Community Psychiatrists support the safe and effective use of LAIs by encouraging mental healthcare professionals to utilize LAIs as an earlier treatment option.

LAI=Long-Acting Injectable 

INVEGA TRINZA® Has Demonstrated Longer Time to Relapse vs Placebo1,4

time-to-relapse-efficacy

A randomized, double-blind, placebo-controlled, long-term maintenance study compared 3-month INVEGA TRINZA® with placebo1,4

total-panss-efficacy

INVEGA TRINZA® provided significant symptom improvement in PANSS total scores

PANSS=Positive and Negative Syndrome Scale

With INVEGA TRINZA® You Can be Confident Adult Patients Receive up to 3 Months of Medication1,2

plasma-concetrations

Due to the difference in median pharmacokinetic profiles between the 2 products (INVEGA TRINZA® and INVEGA SUSTENNA®), caution should be exercised when making a direct comparison of their pharmacokinetic properties.2

The Formulation of INVEGA TRINZA® Allows for Gradual Release of the Medicine1

INVEGA TRINZA® 3-Month Formulation2

formulation

A Retrospective Real-world Claims Analysis Showed Most Schizophrenia Patients Returned for Treatment

After treatment with INVEGA SUSTENNA® for at least 4 months, the majority of adult schizophrenia patients who were transitioned to INVEGA TRINZA® per label* returned for treatment

real-world-2

Based on a retrospective cohort analysis of pharmacy and medical claims data, of adult patients with schizophrenia (n=1603), from the Symphony Health Solutions (SHS) database from May 2014 to September 2016. First data on patient claims for INVEGA TRINZA® were from July 2015.

  • Claims databases such as SHS are subject to billing inaccuracies and missing data
  • Data are real-world usage patterns only; there are no associated clinical/economic outcomes
  • Findings are based on medication dispensed date, not administration of medication

Patient Claims Data

SHS, a robust open-source database, captures prescription transactions for roughly 75% of the US population annually (approximately 260 million patients). The database does not capture services received outside of the SHS network.6

References: 1. INVEGA TRINZA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2019. 2. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 3. National Council for Behavioral Health. Guide to Long-acting Medications for Providers and Organizations. https://www.thenationalcouncil.org/topics/long-acting-medications/. Published June 5, 2019. Accessed June 5, 2019. 4. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830-839. Supplemental data available at: http://archpsyc.jamanetwork.com/article.aspx?articleid=2211343#tab12. Accessed November 8, 2019. 5. Joshi K, Lafeuille MH, Brown B, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-month paliperidone palmitate in the real-world setting. Curr Med Res Opin. 2017;33:10: 1763-1772. 6. Data on file. Symphony Health Solutions. Janssen Pharmaceuticals, Inc., Titusville, NJ.